To identify specific predictive biomarkers, we selected five biomarkers (F5, FLT4, GNPTG, IL-17A, and SFTPB) that were differentially expressed between the R and NR patient groups in both lymphoma cohorts from the top 20% of significantly differentially expressed proteins (p < 0.05). This evidence concerns the gene FLT4 and lymphoma.